Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc

Bullboard Posts

Comment by thianon Dec 28, 2011 5:41am

229 Views

Post# 19353708

RE: RE: RE: Even if the options are reduced

Xtrykr0 they would simply issue new options at a lower price. These people are something else. SP falling as a frigging brick and there the go doing their usual stuff. Rewarding themselves for doing very little for the stakeholder.

I think you make a great point.

Bullboard Posts

Eminent acquires promising Nevada gold project